Oncorus (ONCR)

Company Profile

At Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. Oncorus is advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity to tumor cells. Its lead program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities.

Company profile

Ticker

ONCR

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001671818

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

IRS number

473779757

ONCR stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

2 Nov 22

Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

2 Nov 22

8-K

Entry into a Material Definitive Agreement

14 Sep 22

8-K

Regulation FD Disclosure

4 Aug 22

Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates

4 Aug 22

8-K

Oncorus Appoints Douglas Fambrough to Board of Directors

Departure of Directors or Certain Officers

10 May 22

Latest ownership filings

View all

Financial summary

Financial statements Chart ONCR financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	45.01 mm	45.01 mm	45.01 mm	45.01 mm	45.01 mm	45.01 mm
Cash burn (monthly)	14.41 mm	8.62 mm	6.43 mm	6.30 mm	3.62 mm	5.50 mm
Cash used (since last report)	60.60 mm	36.26 mm	27.05 mm	26.50 mm	15.22 mm	23.13 mm
Cash remaining	-15.60 mm	8.74 mm	17.95 mm	18.50 mm	29.79 mm	21.88 mm
Runway (months of cash)	-1.1	1.0	2.8	2.9	8.2	4.0

Beta Read what these cash burn values mean

Financial data from Oncorus earnings reports.

Institutional ownership, Q3 2022

ONCR institutional ownership history Ownership history

97.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	42	4	+950.0%
Opened positions	38	1	+3700.0%
Closed positions	0	56	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	106.14 mm	92.15 mm	+15.2%
Total shares	25.38 mm	8.91 mm	+184.7%
Total puts	0.00	0.00
Total calls	91.40 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Deerfield Management	3.15 mm	$2.68 mm	NEW
MPM Asset Management	2.85 mm	$2.42 mm	NEW
Flynn James E	2.85 mm	$44.22 mm	0.0%
K2 HealthVentures Equity Trust	2.59 mm	$4.54 mm	0.0%
MPM BioVentures 2014	2.40 mm	$37.31 mm	0.0%
MPM Oncology Impact Management	2.38 mm	$2.02 mm	NEW
CHI Advisors	2.37 mm	$2.01 mm	NEW
Citadel Advisors	1.91 mm	$1.63 mm	NEW
Arkin Moshe	1.07 mm	$6.08 mm	0.0%
FOSUF Fosun International	962.32 k	$818.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Deerfield Management	3.15 mm	+3.15 mm	NEW
MPM Asset Management	2.85 mm	+2.85 mm	NEW
MPM Oncology Impact Management	2.38 mm	+2.38 mm	NEW
CHI Advisors	2.37 mm	+2.37 mm	NEW
Citadel Advisors	1.91 mm	+1.91 mm	NEW
FOSUF Fosun International	962.32 k	+962.32 k	NEW
Sphera Funds Management	540.26 k	+540.26 k	NEW
Vanguard	496.31 k	+496.31 k	NEW
Millennium Management	368.03 k	+368.03 k	NEW
BLK Blackrock	272.36 k	+272.36 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ONCR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.27	15,220	4.11 k	284,697
30 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.27	61,826	16.69 k	1,156,308
30 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.27	61,826	16.69 k	1,156,309
29 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.26	15,538	4.04 k	299,917
29 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.26	63,108	16.41 k	1,218,134
29 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.26	63,107	16.41 k	1,218,135
28 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.25	6,096	1.52 k	315,455
28 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.25	24,757	6.19 k	1,281,242
28 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.25	24,757	6.19 k	1,281,242
27 Dec 22	Flynn James E	Common Stock	Sell	Dispose S	Yes	No	0.27	7,136	1.93 k	321,551